ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.
The ELZA Institute heads to Jeddah for the first SSCRS congress, 24–26 September 2026. Prof. Farhad Hafezi and Nikki Hafezi present four talks spanning personalised cross-linking, epi-on CXL, corneal biomechanics and ELZA-PACE.
Corneal imaging in keratoconus – Scheimpflug tomography, OCT and epithelial mapping – now catches the disease years earlier. How modern scans work, from ELZA.
For two decades, one of the most quietly transformative treatments in eye care has rested on a deceptively simple idea: if you can stiffen the cornea, you can stop a sight-threatening disease in its tracks…
A new ELZA review in Die Ophthalmologie examines the mechanisms, clinical evidence, protocol selection, and indications for PACK-CXL in infectious keratitis.
Nikki and Farhad Hafezi represented ELZA at Vision China 2026, presenting work on keratoconus epidemiology, corneal cross-linking, K-MAP and international research collaboration.
Light for Sight returned to Bukhara to complete second-eye epi-on CXL treatment for two young girls with keratoconus identified through screening in Uzbekistan
Nikki and Farhad Hafezi are representing ELZA in China this week with invited presentations on corneal cross-linking, keratoconus, refractive surgery safety, PACK-CXL, and K-MAP.
